Celldex therapeutics, inc. (CLDX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
REVENUES:
Total Revenues

2,728

887

546

715

1,425

1,766

941

2,763

4,068

3,456

3,924

3,829

1,534

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product Development and Licensing Agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

493

604

453

389

377

334

342

319

284

200

35

43

40

47

30

43

28

40

35

45

40

11

14

1,371

1,399

Contracts and Grants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,727

785

850

1,401

649

1,844

144

1,158

817

392

381

577

940

50

50

52

79

96

54

-

5

-

-

-

-

Product Royalties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,334

3,552

3,006

1,873

2,344

2,358

2,318

1,941

2,502

1,037

1,552

Total Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,220

1,389

1,303

1,790

1,026

2,178

486

1,477

1,101

592

416

620

980

97

2,414

3,647

3,113

2,009

2,433

2,434

2,363

1,952

2,516

2,408

2,951

OPERATING EXPENSES:
Research and Development

11,695

10,339

11,101

10,081

11,151

11,208

11,918

21,448

21,875

23,464

21,915

24,999

25,793

24,559

25,009

25,711

27,447

23,900

24,656

26,490

25,125

27,026

26,185

24,100

27,070

17,804

20,417

15,090

14,090

13,746

11,769

11,114

10,769

9,823

8,594

7,169

6,853

7,215

7,256

Royalty

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,334

3,552

3,006

1,873

2,344

2,358

2,318

1,941

2,502

1,218

1,732

Gain on Sale of Assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

-

General and Administrative

3,666

3,219

3,403

3,908

4,896

4,333

3,722

5,621

5,593

5,894

5,346

6,534

7,229

11,932

6,950

7,790

9,307

11,077

8,487

8,184

6,089

6,249

5,004

4,787

4,582

4,678

3,578

3,411

3,138

2,645

2,835

2,219

2,317

2,344

2,273

2,240

2,336

2,421

2,591

Goodwill Impairment

-

-

-

-

-

0

0

0

90,976

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible Asset Impairment

-

-

-

-

-

-

-

-

-

-

13,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible Asset Impairment

-

-

-

-

-

-

-

-

18,677

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Asset Impairment

-

0

0

0

1,800

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on Fair Value Remeasurement of Contingent Consideration

-234

-318

2,114

1,017

-1,519

1,653

6,935

7,433

13,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on Fair Value Remeasurement of Contingent Consideration

-

-

-

-

-

-

-

-

-

-

-4,600

1,000

3,400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of Acquired Intangible Assets

-

-

0

0

-

0

0

0

224

224

224

224

224

236

254

254

253

252

254

254

253

252

254

254

253

252

254

254

253

254

254

291

291

291

656

483

483

483

658

Total Operating Expenses

15,595

13,876

12,390

12,972

19,366

13,888

8,705

19,636

123,745

28,982

35,885

32,757

36,646

36,727

32,213

33,755

37,007

35,229

33,397

34,928

31,467

33,527

31,443

29,141

31,905

22,734

24,249

18,755

19,815

20,197

17,864

15,497

15,721

14,816

13,841

11,833

12,174

11,287

12,237

Operating Loss

-12,867

-12,989

-11,844

-12,257

-17,941

-12,122

-7,764

-16,873

-119,677

-25,526

-31,961

-28,928

-35,112

-34,853

-29,993

-32,366

-35,704

-33,439

-32,371

-32,750

-30,981

-32,050

-30,342

-28,549

-31,489

-22,114

-23,269

-18,658

-17,401

-16,550

-14,751

-13,488

-13,288

-12,382

-11,478

-9,881

-9,658

-8,879

-9,286

Investment and Other Income, Net

242

2,542

431

478

702

2,720

521

466

780

2,603

398

362

851

2,546

395

414

1,031

755

391

391

807

229

2,260

275

1,586

137

142

161

379

94

105

126

205

-

-

-

-

-

-

Investment and Other Income, Net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

144

79

84

124

95

Interest Expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

85

13

519

310

351

381

411

433

439

438

434

485

332

334

Net Loss Before Income Tax Benefit

-

-

-11,413

-11,779

-

-9,402

-7,243

-16,407

-118,897

-22,923

-31,563

-28,566

-34,261

-

-29,598

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income Tax Benefit

-

-

-

-

-

0

0

0

-765

-

-5,200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Loss

-12,625

-10,447

-11,413

-11,779

-17,239

-9,402

-7,243

-16,407

-118,132

-3,841

-26,363

-28,566

-34,261

-32,307

-29,598

-31,952

-34,673

-32,684

-31,980

-32,359

-30,174

-31,821

-28,082

-28,274

-29,903

-22,062

-23,140

-19,016

-17,332

-16,807

-15,027

-13,773

-13,516

-12,732

-11,772

-10,236

-10,059

-9,087

-

Net Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,525

Basic and Diluted Net Loss Per Common Share

-0.73

-0.52

-0.75

-0.84

-1.40

0.46

-0.66

-1.67

-12.61

-10.15

-0.20

-0.23

-0.28

-18.03

-0.29

-0.32

-0.35

-0.33

-0.32

-0.33

-0.33

-0.36

-0.31

-0.32

-0.33

-0.26

-0.29

-0.24

-0.23

-0.27

-0.25

-0.23

-0.27

-0.28

-0.27

-0.27

-0.31

-0.28

-0.30

Shares Used in Calculating Basic and Diluted Net Loss per Share

17,406

16,497

15,282

13,952

12,297

11,657

10,912

9,829

9,370

-343,210

129,640

125,202

122,648

-271,102

100,672

98,817

98,689

98,717

98,568

98,482

92,437

89,561

89,404

89,361

89,270

83,167

81,015

80,899

74,027

62,507

59,467

58,733

50,145

-

44,136

37,463

-

-

-

COMPREHENSIVE LOSS:
Shares Used in Calculating Basic Net Loss per Share (Note 3) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,047

31,922

31,815

Shares Used in Calculating Diluted Net Loss per Share (Note 3) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,047

31,922

31,815

Net Loss

-12,625

-10,447

-11,413

-11,779

-17,239

-9,402

-7,243

-16,407

-118,132

-3,841

-26,363

-28,566

-34,261

-32,307

-29,598

-31,952

-34,673

-32,684

-31,980

-32,359

-30,174

-31,821

-28,082

-28,274

-29,903

-22,062

-23,140

-19,016

-17,332

-16,807

-15,027

-13,773

-13,516

-12,732

-11,772

-10,236

-10,059

-9,087

-

Other Comprehensive Income (Loss):
Foreign Currency Translation Adjustments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

15

-1

-3

-2

1

0

0

-1

-2

0

1

-1

2

-1

-3

-1

-4

-

-

Unrealized Gain on Marketable Securities

-22

-16

-3

36

19

1

-8

31

-5

-24

11

15

21

-69

-113

36

380

-253

124

-180

11

-33

-121

80

1

-18

138

-140

-54

-30

52

-39

108

-1

-117

15

13

-

-

Comprehensive Loss

-12,647

-10,463

-11,416

-11,743

-17,220

-9,401

-7,251

-16,376

-118,137

-3,865

-26,352

-28,551

-34,240

-32,376

-29,711

-31,916

-34,293

-32,937

-31,856

-32,539

-30,148

-31,855

-28,206

-28,196

-29,901

-22,080

-23,002

-19,157

-17,388

-16,837

-14,974

-13,813

-13,406

-12,734

-11,892

-10,222

-10,050

-

-

Product Development and Licensing Agreements
Total Revenues

2,286

94

55

195

129

551

131

1,667

992

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contracts and Grants
Total Revenues

442

793

491

520

1,296

1,215

810

1,096

3,076

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-